Cardinal Health, Inc. (CAH) - Q1 Fiscal 2026 Form 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025 (Q1 Fiscal 2026). Cardinal Health is a global healthcare services and products company operating primarily through two reportable segments: Pharmaceutical and Specialty Solutions (Pharma) and Global Medical Products and Distribution (GMPD). The company also reports an "Other" segment comprising Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics.
Key Financial Metrics
| Metric | Q1 FY26 (Sep 30, 2025) | Q1 FY25 (Sep 30, 2024) | Change |
|---|---|---|---|
| Total Revenue | $64.0 billion | $52.3 billion | +22% |
| GAAP Operating Earnings | $668 million | $568 million | +18% |
| Non-GAAP Operating Earnings | $857 million | $625 million | +37% |
| GAAP Diluted EPS | $1.88 | $1.70 | +11% |
| Non-GAAP Diluted EPS | $2.55 | $1.88 | +36% |
| Net Earnings (Attributable to CAH) | $450 million | $416 million | +8% |
| Operating Cash Flow | $973 million | ($1,647 million) | Significant Improvement |
| Cash and Equivalents | $4.6 billion | $3.9 billion (Jun 30, 2025) | N/A |
| Total Long-Term Debt | $9.0 billion | $8.5 billion (Jun 30, 2025) | +$0.5 billion |
Material Changes vs. Prior Period
- Revenue Growth: Driven primarily by a 23% increase in the Pharma segment ($59.2B) due to branded and specialty pharmaceutical sales growth, including significant demand for GLP-1 products. The "Other" segment grew 38% due to the acquisition of Advanced Diabetes Supply Group (ADS) and growth in at-Home Solutions.
- Profitability: GAAP operating earnings rose 18%, while Non-GAAP operating earnings surged 37%. This divergence is largely due to the exclusion of acquisition-related costs and amortization in the Non-GAAP measure.
- Acquisition Impact: The quarter included the impact of recent Management Services Organization (MSO) platform acquisitions (GI Alliance, Urology America, Integrated Oncology Network) and the ADS acquisition, which boosted segment profits.
- Interest Expense: Net interest expense increased to $80 million from $32 million year-over-year due to additional debt financing for recent acquisitions.
- Working Capital: Operating cash flow turned positive ($973M) compared to a significant outflow in the prior year, aided by a $2.1 billion increase in accounts payable.
Guidance, Outlook, Risks, and Unusual Items
- Acquisitions: On August 12, 2025, Cardinal Health announced a definitive agreement to acquire Solaris Health for approximately $1.9 billion in cash. The transaction is expected to close subject to regulatory approvals and will be financed via recent debt proceeds and cash on hand.
- Regulatory Risks: Management highlighted uncertainty regarding the Executive Order on "Most-Favored Nation" prescription drug pricing and the potential impact of the "One Big Beautiful Bill Act" (OBBBA) on Medicare/Medicaid participation. These could adversely affect branded pharmaceutical sales and profitability.
- Tariffs: Recent U.S. tariffs on imported goods have increased sourcing costs. While the company is raising prices and seeking alternative sources, there is a risk of supply disruptions and margin compression if costs cannot be fully passed through.
- Opioid Litigation: The company has $4.3 billion accrued for opioid-related settlements. During the quarter, it made $403 million in payments. Future payments are expected through 2038.
- Capital Deployment: The company deployed $375 million for share repurchases (via an Accelerated Share Repurchase program) and $129 million for dividends. It also issued $1.0 billion in new long-term debt (4.5% Notes due 2030 and 5.15% Notes due 2035).
Investor Verification Checklist
- Solaris Health Closing: Verify the closing date and final purchase price adjustments for the $1.9 billion Solaris Health acquisition.
- GLP-1 Sustainability: Assess the sustainability of the revenue growth driven by GLP-1 pharmaceuticals and potential supply constraints.
- Tariff Mitigation: Monitor the company's ability to offset tariff-related cost increases through price hikes without losing market share.
- Opioid Cash Flow: Track the timing and magnitude of future opioid settlement payments against projected operating cash flows.
- Debt Covenants: Confirm continued compliance with the 3.75-to-1 net leverage ratio covenant following the new debt issuance and acquisition financing.